DEOD: uncovering dominant effects of cancer-driver genes based on a partial covariance selection method
暂无分享,去创建一个
[1] D. Pe’er,et al. Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data , 2003, Nature Genetics.
[2] R. Gilbert,et al. Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis? , 2014, Human molecular genetics.
[3] Susumu Goto,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..
[4] Tom H. Pringle,et al. The human genome browser at UCSC. , 2002, Genome research.
[5] A. Jalota-Badhwar,et al. Gene regulation by SMAR1: Role in cellular homeostasis and cancer. , 2011, Biochimica et biophysica acta.
[6] Hyunju Lee,et al. WMAXC: A Weighted Maximum Clique Method for Identifying Condition-Specific Sub-Network , 2014, PloS one.
[7] Fan Zhang,et al. Discovery of pathway biomarkers from coupled proteomics and systems biology methods , 2010, BMC Genomics.
[8] Y. Taketani,et al. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] Dana Pe'er,et al. JISTIC: Identification of Significant Targets in Cancer , 2010, BMC Bioinformatics.
[10] D. Pe’er,et al. An Integrated Approach to Uncover Drivers of Cancer , 2010, Cell.
[11] D. Bertsekas,et al. TWO-METRIC PROJECTION METHODS FOR CONSTRAINED OPTIMIZATION* , 1984 .
[12] Ryan K. Orosco,et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss , 2014, Nature Genetics.
[13] Chris Mungall,et al. AmiGO: online access to ontology and annotation data , 2008, Bioinform..
[14] R. Tibshirani. Regression Shrinkage and Selection via the Lasso , 1996 .
[15] P. Parfrey,et al. Serotonin Transporter Gene (SLC6A4) Variations Are Associated with Poor Survival in Colorectal Cancer Patients , 2012, PloS one.
[16] K. Black,et al. Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era , 2012, PloS one.
[17] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[18] Yan Liu,et al. A central role for TRPS1 in the control of cell cycle and cancer development , 2014, Oncotarget.
[19] S. Rafii,et al. Splitting vessels: Keeping lymph apart from blood , 2003, Nature Medicine.
[20] Jolanta Lissowska,et al. TGF-β Signaling Pathway and Breast Cancer Susceptibility , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[21] P. V. van Diest,et al. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer , 2011, The Journal of pathology.
[22] D. Pe’er,et al. RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation. , 2013, Cancer research.
[23] N. Higham. COMPUTING A NEAREST SYMMETRIC POSITIVE SEMIDEFINITE MATRIX , 1988 .
[24] Paul A. Bates,et al. Global topological features of cancer proteins in the human interactome , 2006, Bioinform..
[25] L. Feng,et al. Insights into significant pathways and gene interaction networks underlying breast cancer cell line MCF-7 treated with 17β-estradiol (E2). , 2014, Gene.
[26] Jie Xu,et al. Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients , 2014, Translational oncology.
[27] M. Duffy,et al. p53 as a target for the treatment of cancer. , 2014, Cancer treatment reviews.
[28] Anne-Marie Cleton-Jansen,et al. FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. , 2005, Cancer research.
[29] Sandhya Rani,et al. Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..
[30] Olufunmilayo I Olopade,et al. MYC in breast tumor progression , 2008, Expert review of anticancer therapy.
[31] D. Radisky,et al. MYC Suppresses Cancer Metastasis by Direct Transcriptional Silencing of αv and β3 Integrin Subunits , 2012, Nature Cell Biology.
[32] B. Győrffy,et al. A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers , 2014, Molecular oncology.
[33] M. Katoh,et al. Comparative genomics on mammalian Fgf3-Fgf4 locus. , 2005, International journal of oncology.
[34] Rainer König,et al. The functional cancer map: A systems-level synopsis of genetic deregulation in cancer , 2011, BMC Medical Genomics.
[35] Natalie Wilson,et al. Human Protein Reference Database , 2004, Nature Reviews Molecular Cell Biology.
[36] Olufunmilayo I Olopade,et al. MYC and Breast Cancer. , 2010, Genes & cancer.
[37] Wei Keat Lim,et al. The transcriptional network for mesenchymal transformation of brain tumors , 2009, Nature.
[38] V. Cormier-Daire,et al. The ADAMTS(L) family and human genetic disorders. , 2011, Human molecular genetics.
[39] Richard A. Johnson,et al. Applied Multivariate Statistical Analysis , 1983 .
[40] David Haussler,et al. PARADIGM-SHIFT predicts the function of mutations in multiple cancers using pathway impact analysis , 2012, Bioinform..
[41] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[42] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.